Clinical trial · Interventional
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
NCT07384013CI-TRIAL-00102312recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Coagulation Defect | — | UNRESOLVED | — |
| Oncologic Diseases | — | UNRESOLVED | — |
| Pain Management | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| metamizole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort 1: Chronic metamizole users
- description
- Patients receiving Optalgin prior to study enrollment
- interventionNames
- Drug: metamizole
- type
- EXPERIMENTAL
- label
- Cohort 2: New metamizole users
- description
- Patients receiving Optalgin after to study enrollment
- interventionNames
- Drug: metamizole
Primary outcomes (1)
- measure
- Change in DOAC
- timeFrame
- 1- Baseline 2- End Of Treatment 3- Day 3 Post treatment 4- Day 5 Post Treatment 5- Day 7 Post treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult oncology patients (≥18 years old). * Receiving apixaban or rivaroxaban for anticoagulation. * New/current metamizole users taking at least 1g TID for pain management. * Platelets ≥100×10⁹/L * ECOG PS\<3 * Provided informed consent Exclusion Criteria: * History of allergic reaction to metamizole or DOACs. * Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT/zonda)
References
Publications (0)
Data not yet available
No reference posted for this study.